LEADER 05613nam 2200757Ia 450 001 9910826980703321 005 20200520144314.0 010 $a9786612688393 010 $a9781282688391 010 $a1282688391 010 $a9780470561416 010 $a0470561416 010 $a9780470561409 010 $a0470561408 035 $a(CKB)2550000000005941 035 $a(EBL)477779 035 $a(OCoLC)609853664 035 $a(SSID)ssj0000354545 035 $a(PQKBManifestationID)11276005 035 $a(PQKBTitleCode)TC0000354545 035 $a(PQKBWorkID)10314524 035 $a(PQKB)11457422 035 $a(MiAaPQ)EBC477779 035 $a(Au-PeEL)EBL477779 035 $a(CaPaEBR)ebr10360991 035 $a(CaONFJC)MIL268839 035 $a(PPN)243307217 035 $a(OCoLC)1292942762 035 $a(FINmELB)ELB178829 035 $a(Perlego)2765577 035 $a(EXLCZ)992550000000005941 100 $a20090519d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNovel therapeutic targets for anti-arrhythmic drugs /$fedited by George E. Billman 205 $a1st ed. 210 $aHoboken, NJ $cJohn Wiley & Sons$dc2010 215 $a1 online resource (612 p.) 300 $aDescription based upon print version of record. 311 08$a9780470261002 311 08$a0470261005 320 $aIncludes bibliographical references and index. 327 $aNOVEL THERAPEUTIC TARGETS FOR ANTIARRHYTHMIC DRUGS; CONTENTS; Acknowledgments; Contributors; 1. Introduction; References; 2. Myocardial K(+) Channels: Primary Determinants of Action Potential Repolarization; 2.1 Introduction; 2.2 Action Potential Waveforms and Repolarizing K(+) Currents; 2.3 Functional Diversity of Repolarizing Myocardial K(+) Channels; 2.4 Molecular Diversity of K(+) Channel Subunits; 2.5 Molecular Determinants of Functional Cardiac I(to) Channels; 2.6 Molecular Determinants of Functional Cardiac I(K) Channels; 2.7 Molecular Determinants of Functional Cardiac Kir Channels 327 $a2.8 Other Potassium Currents Contributing to Action Potential Repolarization2.8.1 Myocardial K(+) Channel Functioning in Macromolecular Protein Complexes; References; 3. The "Funny" Pacemaker Current; 3.1 Introduction: The Mechanism of Cardiac Pacemaking; 3.2 The "Funny" Current; 3.2.1 Historical Background; 3.2.2 Biophysical Properties of the I(f) Current; 3.2.3 Autonomic Modulation; 3.2.4 Cardiac Distribution of I(f); 3.3 Molecular Determinants of the I(f) Current; 3.3.1 HCN Clones and Pacemaker Channels; 3.3.2 Identification of Structural Elements Involved in Channel Gating 327 $a3.3.3 Regulation of Pacemaker Channel Activity: "Context" Dependence and Protein-Protein Interactions3.3.4 HCN Gene Regulation; 3.4 Blockers of Funny Channels; 3.4.1 Alinidine (ST567); 3.4.2 Falipamil (AQ-A39), Zatebradine (UL-FS 49), and Cilobradine (DK-AH269); 3.4.3 ZD7288; 3.4.4 Ivabradine (S16257); 3.4.5 Effects of the Heart Rate Reducing Agents on HCN Isoforms; 3.5 Genetics of HCN Channels; 3.5.1 HCN-KO Models; 3.5.2 Pathologies Associated with HCN Dysfunctions; 3.6 HCN-Based Biological Pacemakers; References; 4. Arrhythmia Mechanisms in Ischemia and Infarction; 4.1 Introduction 327 $a4.1.1 Modes of Ischemia, Phases of Arrhythmogenesis4.1.2 Trigger-Substrate-Modulating Factors; 4.2 Arrhythmogenesis in Acute Myocardial Ischemia; 4.2.1 Phase 1A; 4.2.2 Phase 1B; 4.2.3 Arrhythmogenic Mechanism: Trigger; 4.2.4 Catecholamines; 4.3 Arrhythmogenesis During the First Week Post MI; 4.3.1 Mechanisms; 4.3.2 The Subendocardial Purkinje Cell as a Trigger 24-48 H Post Occlusion; 4.3.3 Five Days Post-Occlusion: Epicardial Border Zone; 4.4 Arrhythmia Mechanisms in Chronic Infarction; 4.4.1 Reentry and Focal Mechanisms; 4.4.2 Heterogeneity of Ion Channel Expression in the Healthy Heart 327 $a4.4.3 Remodeling in Chronic Myocardial Infarction4.4.4 Structural Remodeling; 4.4.5 Role of the Purkinje System; References; 5. Antiarrhythmic Drug Classification; 5.1 Introduction; 5.2 Sodium Channel Blockers; 5.2.1 Mixed Sodium Channel Blockers (Vaughan Williams Class Ia); 5.3 Inhibitors of the Fast Sodium Current with Rapid Kinetics (Vaughan Williams Class Ib); 5.3.1 Lidocaine; 5.3.2 Mexiletine; 5.4 Inhibitors of the Fast Sodium Current with Slow Kinetics (Vaughan Williams Class Ic); 5.4.1 Flecainide; 5.4.2 Propafenone 327 $a5.5 Inhibitors of Repolarizing K(+) Currents (Vaughan Williams Class III) 330 $aProfiles potential treatment approaches for cardiac arrhythmias Cardiac arrhythmias of ventricular origin are responsible for the deaths of nearly half a million Americans each year while atrial fibrillation accounts for about 2.3 million cases per year, a rate that is projected to increase 2.5 fold over the next half century. Effectively managing these cardiac rhythm disorders remains a major challenge for both caregivers and the pharmaceutical industry. Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments f 606 $aMyocardial depressants 606 $aArrhythmia$xChemotherapy 615 0$aMyocardial depressants. 615 0$aArrhythmia$xChemotherapy. 676 $a615.716 676 $a616.128061 701 $aBillman$b George Edward$f1954-$01723738 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910826980703321 996 $aNovel therapeutic targets for anti-arrhythmic drugs$94125222 997 $aUNINA LEADER 03221nam 22006735 450 001 9910483285803321 005 20250610110238.0 010 $a9783030661397 010 $a3030661393 024 7 $a10.1007/978-3-030-66139-7 035 $a(CKB)4100000011763303 035 $a(MiAaPQ)EBC6478289 035 $a(DE-He213)978-3-030-66139-7 035 $a(MiAaPQ)EBC29081803 035 $a(EXLCZ)994100000011763303 100 $a20210211d2021 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe Afterdeath of the Holocaust /$fby Lawrence L. Langer 205 $a1st ed. 2021. 210 1$aCham :$cSpringer International Publishing :$cImprint: Palgrave Macmillan,$d2021. 215 $a1 online resource (xx, 247 pages) $cillustrations 225 1 $aThe Holocaust and its Contexts,$x2731-572X 311 08$a9783030661380 311 08$a3030661385 327 $a1. The Afterdeath of the Holocaust -- 2. My Life with Holocaust Death -- 3. Redemptive and Unredemptive Holocaust Memory -- 4. Representing and Misrepresenting the Holocaust -- 5. Charlotte Delbo's Auschwitz and After -- 6. Holocaust Fact and Holocaust Fiction: The Dual Vision of H.G. Adler -- 7. Beyond Testimony: The Literary Design of Primo Levi's If This is a Man. 8. The Legacy of Holocaust Deathscapes -- 9. Memory and Invention in Olga Lengyel's Five Chimneys -- 10. Ner Ot: The Memorial Candle as Symbol in the Art of Samuel Bak. 330 $aThis book consists of ten essays that examine the ways in which language has been used to evoke what Lawrence L. Langer calls the 'deathscape' and the 'hopescape' of the Holocaust. The chapters in this collection probe the diverse impacts that site visits, memoirs, survivor testimonies, psychological studies, literature and art have on our response to the atrocities committed by the Germans during World War II. Langer also considers the misunderstandings caused by erroneous, embellished and sentimental accounts of the catastrophe, and explores some reasons why they continue to enter public and printed discourse with such ease. 410 0$aThe Holocaust and its Contexts,$x2731-572X 606 $aWorld War, 1939-1945 606 $aHistoriography 606 $aHistory$xMethodology 606 $aIntellectual life$xHistory 606 $aCollective memory 606 $aHistory of World War II and the Holocaust 606 $aHistoriography and Method 606 $aIntellectual History 606 $aMemory Studies 615 0$aWorld War, 1939-1945. 615 0$aHistoriography. 615 0$aHistory$xMethodology. 615 0$aIntellectual life$xHistory. 615 0$aCollective memory. 615 14$aHistory of World War II and the Holocaust. 615 24$aHistoriography and Method. 615 24$aIntellectual History. 615 24$aMemory Studies. 676 $a940.5318072 700 $aLanger$b Lawrence L.$0464902 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910483285803321 996 $aThe afterdeath of the Holocaust$92850992 997 $aUNINA 999 $aBOOK